Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Risperidal Consta (risperidone)
- Development stage
- Approved
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Risperdal Consta is a long-acting, atypical antipsychotic injection consisting of risperidone encapsulated in biodegradable polylactide-co-glycolide (PLGA) microspheres. Developed using Alkermes' proprietary Medisorb drug-delivery technology, it is designed to provide sustained therapeutic levels of risperidone over a two-week period following deep intramuscular injection, thereby improving treatment adherence in patients with chronic psychiatric conditions. Risperidone acts primarily as a high-affinity antagonist at serotonin 5-HT2A and dopamine D2 receptors, balancing monoaminergic neurotransmission to alleviate both positive and negative symptoms of psychosis. It is indicated for the treatment of schizophrenia and as monotherapy or adjunctive therapy for the maintenance treatment of Bipolar I Disorder.
- Brand names
- HengdeRisperdal ConstaRisperidal Consta
- Other names
- risperidone extended-release injectable suspensionrisperidone long-acting injectionrisperidone microspheres
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)HTR1D (5-hydroxytryptamine receptor 1D)HTR2A (Serotonin receptor 5-HT2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)ADRA2A (α2A)
Beyond the preview
Go deeper on Risperidal Consta (risperidone).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Risperidal Consta (risperidone).